ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2097

Adiponectin Is Associated with Pro-Inflammatory Cytokines in Autoantibody Positive First-Degree Relatives (FDRs) of Patients with Rheumatoid Arthritis

Jan M. Hughes-Austin1, Kevin D. Deane2, Lezlie A. Derber3, Gary O. Zerbe4, Dana M. Dabelea1, Jeremy Sokolove5, William H. Robinson6, V. Michael Holers7 and Jill M. Norris8, 1Epidemiology, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 2Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 3University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, 4Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 5Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 6Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 7Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, 8Epidemiology, Colorado School of Public Health, Aurora, CO

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adipocytokines, autoantibodies, inflammation and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose: While adiponectin is generally considered an anti-inflammatory adipokine, it has also been shown to participate in active RA in inflammatory, matrix-destructive and fibrotic processes leading to joint destruction. Because adiponectin’s role as a pro- or anti-inflammatory adipokine has been controversial in situations of autoimmunity and chronic inflammation, we sought to determine the relationship of adiponectin to rheumatoid arthritis (RA)-related autoantibodies and markers of inflammation in a population without RA, but at increased risk for future development of the disease.

Methods: We selected all visits of 113 FDRs who were positive for rheumatoid factor (RF), RF isotypes IgM, IgG, IgA, or anti-cyclic citrullinated peptide (anti-CCP2) at least once, and 100 FDRs who were never autoantibody positive.  In blood obtained from these 391 visits, we measured cytokines/chemokines, high-sensitivity C-reactive protein (hsCRP), and adiponectin.  As a comprehensive measure of inflammation, we calculated a Cytokine Score by summing all cytokine/chemokine levels, weighted by their regression coefficients for RA-autoantibody association.  We first compared the effect of adiponectin on two autoantibody phenotypes: positivity for RF, and positivity for the high-risk autoantibody profile (HRP) (positive for anti-CCP2 and/or ≥ 2 RF isotypes) that we have shown in previous work to be highly specific (>96%) for future RA; and then tested the interaction between autoantibodies and adiponectin on markers of inflammation using mixed models to account for multiple samples per FDR.  All analyses were adjusted for age, sex, ethnicity, body mass index, pack-years of smoking, a delay in sample processing, and current use of statins.

Results: Adiponectin was not associated with either RF (p=0.44) or HRP (p=0.60) positivity.   Adiponectin was inversely associated with hsCRP (β=-0.31 ± 0.10; p=0.002) and IL-5 (β=-0.21 ± 0.10; p=0.044).   The relationship between adiponectin and TNF-α, GM-CSF, and the Cytokine Score differed by HRP status, where a 10% increase in adiponectin resulted in a 5% increase in TNFa and 4% increase in GM-CSF among HRP+ FDRS; whereas no association was observed among HRP- FDRs (Interaction p=0.016, p=0.028 for TNF-α and GM-CSF, respectively). Similarly, a 10% increase in adiponectin was associated with a 2% increase in Cytokine Score among HRP+ FDRs, but not in HRP- FDRs (Interaction p=0.038). 

Conclusion: In a population without RA, elevations of adiponectin were associated with elevations of several pro-inflammatory cytokines as well as a marker of overall inflammation, Cytokine Score, in the setting of autoantibody positivity; and were inversely associated with elevations of another marker of inflammation, hsCRP.  These findings indicate that adiponectin may have a complex role in early RA-related autoimmunity and inflammation, and that adiponectin may respond differentially according to inflammatory triggers and functions.  Further study is needed to determine the role of adiponectin in early RA pathogenesis.


Disclosure:

J. M. Hughes-Austin,
None;

K. D. Deane,
None;

L. A. Derber,
None;

G. O. Zerbe,
None;

D. M. Dabelea,
None;

J. Sokolove,
None;

W. H. Robinson,
None;

V. M. Holers,
None;

J. M. Norris,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adiponectin-is-associated-with-pro-inflammatory-cytokines-in-autoantibody-positive-first-degree-relatives-fdrs-of-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology